Mineral and Bone Disease in Kidney Transplant Recipients

Overview

Journal Curr Osteoporos Rep

Publisher Current Science

Specialties Endocrinology
Orthopedics

Date 2018 Nov 4

PMID 30390201

Citations 6

Authors

Ariella M Altman

Stuart M Sprague

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Despite metabolic improvements following kidney transplantation, transplant recipients still often suffer from complex mineral and bone disease after transplantation.

Recent Findings: The pathophysiology of post-transplant disease is unique, secondary to underlying pre-transplant mineral and bone disease, immunosuppression, and changing kidney function. Changes in modern immunosuppression regimens continue to alter the clinical picture. Modern management includes reducing cumulative steroid exposure and correcting the biochemical abnormalities in mineral metabolism. While bone mineral density screening appears to help predict fracture risk and anti-osteoporotic therapy appears to have a positive effect on bone mineral density, more data regarding specific treatment is necessary. Patients with mineral and bone disease after kidney transplantation require special care in order to properly manage and mitigate their mineral and bone disease. Recent changes in clinical management of transplant patients may also be changing the implications on patients' mineral and bone disease.

Citing Articles

Relation of testosterone level and other factors with bone mineral density in male kidney transplant recipients: a cross-sectional study.

Naga Y, Sharaki O, Azzam E, Farag E, Zeid M BMC Nephrol. 2023; 24(1):271.

PMID: 37710199 PMC: 10502991. DOI: 10.1186/s12882-023-03318-8.

Mineral and bone disorder after kidney transplantation: a single-center cohort study.

Sun L, Wang Z, Zheng M, Hang Z, Liu J, Gao X Ren Fail. 2023; 45(1):2210231.

PMID: 37183797 PMC: 10187110. DOI: 10.1080/0886022X.2023.2210231.

Drug-induced Fanconi syndrome in patients with kidney allograft transplantation.

Tang Z, Li T, Dai H, Feng C, Xie X, Peng F Front Immunol. 2022; 13:979983.

PMID: 36059468 PMC: 9437944. DOI: 10.3389/fimmu.2022.979983.

Bone volume, mineral density, and fracture risk after kidney transplantation.

Keronen S, Martola L, Finne P, Burton I, Tong X, Kroger H PLoS One. 2022; 17(3):e0261686.

PMID: 35349587 PMC: 8963906. DOI: 10.1371/journal.pone.0261686.

Bone Mineral Density Changes in Long-Term Kidney Transplant Recipients: A Real-Life Cohort Study of Native Vitamin D Supplementation.

Battaglia Y, Bellasi A, Bortoluzzi A, Tondolo F, Esposito P, Provenzano M Nutrients. 2022; 14(2).

PMID: 35057505 PMC: 8780110. DOI: 10.3390/nu14020323.

References

Lane N, Lukert B . The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am. 1998; 27(2):465-83. DOI: 10.1016/s0889-8529(05)70017-7. View

Kan S, Ning G, Chen L, Zhou Y, Sun J, Feng S . Efficacy and Safety of Bisphosphonates for Low Bone Mineral Density After Kidney Transplantation: A Meta-Analysis. Medicine (Baltimore). 2016; 95(5):e2679. PMC: 4748922. DOI: 10.1097/MD.0000000000002679. View

Puccini M, Ceccarelli C, Meniconi O, Zullo C, Prosperi V, Miccoli M . Near total parathyroidectomy for the treatment of renal hyperparathyroidism. Gland Surg. 2018; 6(6):638-643. PMC: 5750313. DOI: 10.21037/gs.2017.09.12. View

Prakobsuk S, Sirilak S, Vipattawat K, Taweesedt P, Sumethkul V, Kantachuvesiri S . Hyperparathyroidism and increased fractional excretion of phosphate predict allograft loss in long-term kidney transplant recipients. Clin Exp Nephrol. 2016; 21(5):926-931. DOI: 10.1007/s10157-016-1370-9. View

Dulfer R, Franssen G, Hesselink D, Hoorn E, van Eijck C, van Ginhoven T . Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. Br J Surg. 2017; 104(7):804-813. DOI: 10.1002/bjs.10554. View

Wesseling-Perry K, Tsai E, Ettenger R, Juppner H, Salusky I . Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23?. Nephrol Dial Transplant. 2011; 26(11):3779-84. PMC: 3247799. DOI: 10.1093/ndt/gfr126. View

Rodan G, Fleisch H . Bisphosphonates: mechanisms of action. J Clin Invest. 1996; 97(12):2692-6. PMC: 507360. DOI: 10.1172/JCI118722. View

McGregor R, Li G, Penny H, Lombardi G, Afzali B, Goldsmith D . Vitamin D in renal transplantation - from biological mechanisms to clinical benefits. Am J Transplant. 2014; 14(6):1259-70. PMC: 4441280. DOI: 10.1111/ajt.12738. View

Cianciolo G, Galassi A, Capelli I, Angelini M, La Manna G, Cozzolino M . Vitamin D in Kidney Transplant Recipients: Mechanisms and Therapy. Am J Nephrol. 2016; 43(6):397-407. DOI: 10.1159/000446863. View

10.

Cejka D, Kodras K, Bader T, Haas M . Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1-34): A Pilot Study. Kidney Blood Press Res. 2010; 33(3):221-6. DOI: 10.1159/000316708. View

11.

Gregorini M, Sileno G, Pattonieri E, Corradetti V, Abelli M, Ticozzelli E . Understanding Bone Damage After Kidney Transplantation: A Retrospective Monocentric Cross Sectional Analysis. Transplant Proc. 2017; 49(4):650-657. DOI: 10.1016/j.transproceed.2017.02.023. View

12.

Economidou D, Dovas S, Papagianni A, Pateinakis P, Memmos D . FGF-23 Levels before and after Renal Transplantation. J Transplant. 2010; 2009:379082. PMC: 2809417. DOI: 10.1155/2009/379082. View

13.

Brunova J, Kratochvilova S, Stepankova J . Osteoporosis Therapy With Denosumab in Organ Transplant Recipients. Front Endocrinol (Lausanne). 2018; 9:162. PMC: 5915642. DOI: 10.3389/fendo.2018.00162. View

14.

Cueto-Manzano A, Konel S, Hutchison A, Crowley V, France M, Freemont A . Bone loss in long-term renal transplantation: histopathology and densitometry analysis. Kidney Int. 1999; 55(5):2021-9. DOI: 10.1046/j.1523-1755.1999.00445.x. View

15.

Kawarazaki H, Shibagaki Y, Fukumoto S, Kido R, Ando K, Nakajima I . Natural history of mineral and bone disorders after living-donor kidney transplantation: a one-year prospective observational study. Ther Apher Dial. 2011; 15(5):481-7. DOI: 10.1111/j.1744-9987.2011.00932.x. View

16.

Filler G, Liu D, Sharma A, Grimmer J . Are fibroblast growth factor 23 concentrations in renal transplant patients different from non-transplanted chronic kidney disease patients?. Pediatr Transplant. 2011; 16(1):73-7. DOI: 10.1111/j.1399-3046.2011.01613.x. View

17.

Josephson M, Schumm L, Chiu M, Marshall C, Thistlethwaite J, Sprague S . Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation. 2004; 78(8):1233-6. DOI: 10.1097/01.tp.0000137937.44703.42. View

18.

Naylor K, Leslie W, Hodsman A, Rush D, Garg A . FRAX predicts fracture risk in kidney transplant recipients. Transplantation. 2014; 97(9):940-5. DOI: 10.1097/01.TP.0000438200.84154.1a. View

19.

Zhang R, Chouhan K . Metabolic bone diseases in kidney transplant recipients. World J Nephrol. 2013; 1(5):127-33. PMC: 3782213. DOI: 10.5527/wjn.v1.i5.127. View

20.

Pande S, Ritter C, Rothstein M, Wiesen K, Vassiliadis J, Kumar R . FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol. 2006; 104(1):p23-32. PMC: 4446726. DOI: 10.1159/000093277. View